Advancing Management Strategies in Metastatic Colon Cancer: Protocols, Targets, and Immunotherapies

SELF STUDY / ENDURING - ESTIMATED TIME TO COMPLETE ACTIVITY: 50 Minutes

Overview

This program provides an in-depth examination of metastatic colon cancer management, emphasizing current treatment protocols, molecular targets, and the role of immunotherapies. Participants will gain insights into the latest systemic therapies and learn how to incorporate genetic profiling into treatment decisions. The course also covers the significance of RAS and BRAF mutations, HER2 amplification, and explores the evolving role of immunotherapy, particularly in patients with specific genetic profiles. 

Target Audience

This CME initiative was designed for oncologists, surgeons, radiation oncologists, NPs, PAs, pharmacists, nurses, and other healthcare professionals involved in the treatment of patients with cancer.

Learning Objectives

1. Review standard treatment protocols in management of first line metastatic colon cancer
2. Identify molecular targets common to colon cancer management
3. Discuss the role of immunotherapy in treatment of metastatic colon cancer                                                                                                           

Course summary
Available credit: 
  • 0.75 AMA PRA Category 1 Credit™
    Horizon CME designates this Enduring activity for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  • 0.75 ANCC
    This activity has been planned and implemented in accordance with the accreditation requirements and policies of the American Nurses Credentialing Center’s Commission on Accreditation through the joint providership of the Nurse Practitioner Healthcare Foundation and Horizon CME. The Nurse Practitioner Healthcare Foundation is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation. NPHF is awarding the contact hours and is responsible for adherence to the ANCC criteria. Upon completion, NPs and RNs will be awarded up to 0.75 credit.
Course opens: 
01/22/2025
Course expires: 
01/22/2026
Cost:
$0.00
Rating: 
0

Faculty

Valerie Lee, MD

Valerie Lee, MD is an Assistant Professor in the Division of Gastrointestinal Cancers at the Sidney Kimmel Comprehensive Cancer at Johns Hopkins.  She graduated summa cum laude with a BA in biochemical sciences from Harvard University in 2007.  She then went on to receive her medical degree from Columbia University College of Physicians and Surgeons in 2011, and then remained on to complete her internship and residency in internal medicine at New York Presbyterian-Columbia.  In 2014 she attended Johns Hopkins to pursue her medical oncology fellowship and joined the faculty as a GI medical oncologist in July 2016 with her primary practice at Sibley Memorial Hospital in DC.

She has a primary interest in the care of patients with gastrointestinal malignancies and has a particular interest in developing clinical trials for the treatment of patients with colorectal cancers.  She has run multiple trials investigating the combination of vaccines with immunotherapy in pancreas cancers and the role of combination therapies in metastatic colorectal cancer.

Disclosures:

In accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education, Horizon CME (HCME) ensures that continuing education activities are balanced, independent, objective, and scientifically rigorous. 

All persons in a position to influence the content of an accredited continuing education activity provided by Horizon CME are required to disclose to HCME any relevant financial relationships with ineligible companies within the past 24 months. All reported relevant financial relationships have been mitigated by Horizon CME.

Valerie Lee, MD discloses an Advisory Board relationship with Sirtex during the past 24 months. 

Available Credit

  • 0.75 AMA PRA Category 1 Credit™
    Horizon CME designates this Enduring activity for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  • 0.75 ANCC
    This activity has been planned and implemented in accordance with the accreditation requirements and policies of the American Nurses Credentialing Center’s Commission on Accreditation through the joint providership of the Nurse Practitioner Healthcare Foundation and Horizon CME. The Nurse Practitioner Healthcare Foundation is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation. NPHF is awarding the contact hours and is responsible for adherence to the ANCC criteria. Upon completion, NPs and RNs will be awarded up to 0.75 credit.

Price

Cost:
$0.00
Please login or register to take this course.

There are no fees for participating and receiving CME credit for this enduring activity. To receive CME credit participants must:

  1. Read the CME/CE information and faculty disclosures.
  2. Participate in the online activity.
  3. Complete the post-test
  4. Submit the evaluation form

DISCLAIMER:

This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.

Required Hardware/software

Access to the internet is required.

Supported Browsers:

Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above

Google Chrome 28.0+ for Windows, Mac OS, or Linux

Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux

Safari 6.0+ for Mac OSX 10.7 and above

 

Supported Phones & Tablets:

 Android 4.0.3 and above

iPhone/iPad with iOS 6.1 or above